Schonfeld Strategic Advisors LLC Erasca, Inc. Transaction History

Schonfeld Strategic Advisors LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$2.57 - $3.3 $16,705 - $21,450	6,500 Added 45.14%	20,900 $57,000
Q1 2023 May 15, 2023	BUY	$2.74 - $4.44 $39,456 - $63,936	14,400 New	14,400 $43,000
Q3 2022 Nov 14, 2022	SELL	$5.82 - $10.68 $47,142 - $86,508	-8,100 Reduced 31.03%	18,000 $140,000
Q2 2022 Aug 15, 2022	SELL	$4.58 - $8.72 $135,110 - $257,240	-29,500 Reduced 53.06%	26,100 $146,000
Q1 2022 May 16, 2022	BUY	$8.6 - $15.48 $478,160 - $860,688	55,600 New	55,600 $478,000

140

229M

28.7K

117K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $310M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.